Table 4.

Characteristics of the "New-wave" direct acting antivirals and the most important variables associated with sustained virological response

Drug	Characteristics	Resistance-associated	SVR predictive factors	OR1	P-value1
Sofosbuvir	Nucleotide analogue HCV NS5B	HCV mutation S282T	Genotype 1			McHutchison et al[15]
	Polymerase inhibitor		Cirrhosis: no vs yes	3.93	0.0018	Neutrino study
	Against all HCV genotypes		IL28B: CC vs CT/TT	7.99	0.006
			RBV exposure (mg/kg per day)	1.39	0.0005
			Genotypes 2 and 3
			HCV genotypes 2 vs 3	42.49	< 0.0001	Fission study
			Cirrhosis: no vs yes	2.94	0.005
			HCV RNA baseline: < vs ≥ 6 Log IU/mL	2.33	0.009
			RBV exposure (mg/kg per day)	1.26	0.002
Simeprevir	NS3/4A serine protease inhibitor	Q80K-HCV subtype 1a	HCV 1a: Q80K: no vs yes	0.19	1.7 × 10-5	Jacobson et al[61]
	HCV genotype 1	R155K	F0-F2 vs F3-F4	2.09	0.029	Quest-1 study
		D168V - HCV subtype 1b	IL28B: CC vs CT/TT	5.11	1.3 × 10-4
			HCV RNA baseline: ≤ vs > 800.000 IU/mL	3.13	0.028
Daclatasvir	NS5A replication complex inhibitor	NS3 polymorphisms	HCV genotype 1a vs 1b	2.82	0.025	Hézode et al[63]
	Against all HCV genotypes	NS5A-A30K	HCV genotypes 2 vs 3	1.31	0.740	Sulkowski et al[46]
Ledipasvir	HCV NS5A replication complex inhibitor					Afdhal et al[67]
	HCV genotype 1
ABT-450	NS3/4A protease inhibitor		Treatment vs placebo	7.19	4.3 × 20-11	Feld et al[70]
Ritonavir	HCV NS5A replication complex inhibitor
Ombitasvir	HCV NS5A inhibitor (Pangenotipic)		HCV genotype 1a
Dasabuvir	HCV NS5B RNA non-nucleoside polymerase inhibitor		Ribavirin: with vs without	3.50	0.038	Ferenci et al[69]
	HCV genotype 1

¹Statistical analyses were performed using Fisher’s test, two-tailed. An alpha error < 5% was considered. IL28B: Interleukin-28B; HCV: Hepatitis C virus; SVR: Sustained virologic response; RBV: Ribavirin.